此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

BKM120 与顺铂和 XRT 在头颈部高危局部晚期鳞状细胞癌中的 Ib 期研究

2026年10月21日 更新者:Robert Haddad, MD、Dana-Farber Cancer Institute

BKM120 与每周顺铂联合放疗治疗头颈部高危局部晚期鳞状细胞癌的 Ib 期研究

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

研究概览

详细说明

  • This phase Ib study is combining standard chemoradiotherapy with weekly cisplatin and BKM120 to assess tolerability of this combination in high risk patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). The investigators will also obtain preliminary information about the efficacy of this treatment.
  • The participant will receive the study drug buparlisib once daily, by mouth, for 45 days. The participant will be given a study drug-dosing diary for each cycle. It will include special instructions for taking the study drug at home.
  • The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses.
  • All participants will receive weekly cisplatin injection. Cisplatin will be given intra-venously (IV) on days: (1, 8, 15, 22, 29, 36 and 43) at DFCI.
  • All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks, delivered at DFCI. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.
  • The investigators would like to keep track of the participant's medical condition. Follow-up will continue every 4 to 12 weeks after the end of treatment for the first year and at the investigator's discretion thereafter.

研究类型

介入性

注册 (实际的)

23

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Dana-Farber Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent.
  • Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries.
  • >10 pack years of tobacco use
  • Age ≥ 18 years
  • ECOG performance status ≤ 2
  • At least one site of measurable disease
  • Adequate bone marrow function as shown by: ANC > 1.5 x 109/L, Platelets >100 x 109/L, Hb >9 g/dL
  • Total calcium (corrected for serum albumin) within normal limits
  • Magnesium ≥ the lower limit of normal
  • Potassium within normal limits for the institution.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
  • Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
  • Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
  • Serum amylase ≤ ULN
  • Serum lipase ≤ ULN
  • Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)
  • Signed informed consent
  • INR ≤ 2

Exclusion Criteria:

  • Distant metastatic disease
  • Less than or equal to 10 pack years of tobacco history
  • Received prior chemotherapy
  • Received prior radiation to the head and neck or adjacent anatomical site
  • Received prior treatment with a P13K inhibitor.
  • Known hypersensitivity to BKM120 or to its excipients
  • Acute or chronic liver, renal disease or pancreatitis
  • Mood disorders ≥ CTCAE grade 3
  • Diarrhea ≥ CTCAE grade 2
  • Active cardiac disease
  • History of cardiac dysfunction including any of the following:
  • Patient has poorly
  • Impairment of gastrointestinal (GI) function
  • Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
  • Chronic treatment with steroids or another immunosuppressive agent.
  • Herbal medications and certain fruits within 7 days prior to starting study drug.
  • Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Appendix B for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed).
  • Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  • Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant.
  • Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
  • Known diagnosis of human immunodeficiency virus (HIV) infection
  • History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Level 1
  • 40 mg BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.
  • Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
  • Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

其他名称:
  • 布帕利西布

Cisplatin is a chemotherapy drug

其他名称:
  • 铂醇
  • 铂金-AQ

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

其他名称:
  • 调强放射治疗
实验性的:Dose Level 2
  • 40 mg BKM120 will be administered orally daily for 45 days.
  • Cisplatin: Starting Dose 35 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).
  • Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks.

BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.

其他名称:
  • 布帕利西布

Cisplatin is a chemotherapy drug

其他名称:
  • 铂醇
  • 铂金-AQ

IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells

其他名称:
  • 调强放射治疗

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Tolerated Dose of Cisplatin
大体时间:While on treatment, up to 66 days

The trial uses 3+3 design to determine maximum tolerated dose (MTD).

While on treatment, up to 66 days
Maximum Tolerated Dose of BKM120
大体时间:While on treatment, up to 66 days

The trial uses 3+3 design to determine maximum tolerated dose (MTD).

While on treatment, up to 66 days

次要结果测量

结果测量
措施说明
大体时间
Best Overall Response
大体时间:Measured at end of treatment, up to 66 days

The best overall response for each patient is given per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) criteria:

Complete Response (CR) - Disappearance of all target and non-target lesions and lymph node short axis is <10 mm and no new lesions

Partial Response (PR)

  • Disappearance of target lesions and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions or
  • >=30% decrease in sum of target lesion diameter and no new lesions

Stable Disease (SD)

- Less than 5 mm increase in target lesion diameter unless it results in a >=20% increase in diameter and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions

Progressive Disease (PD)

  • >20% increase in target lesion diameter, must be an absolute increase of 5mm or
  • Substantial worsening in non-target lesion or
  • New lesion present
Measured at end of treatment, up to 66 days
Median Time to Progression
大体时间:Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)

The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months.

Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
24 Month Overall Survival
大体时间:Up to 24 months

The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years.

Up to 24 months
Median Anxiety Score Change
大体时间:From baseline to cycle 9, up to 66 days.

The median change in score on the Generalized Anxiety Disorder - 7 (GAD-7) questionnaire from baseline to cycle 9.GAD-7 has 7 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 21. Higher score represents worse anxiety.

From baseline to cycle 9, up to 66 days.
Median Depression Score Change
大体时间:From baseline to cycle 9, up to 66 days.

The median change in score on the Patient Health Questionnaire - 9 (PHQ-8) from baseline to cycle 9. PHQ-9 has 9 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 27. Higher score represents worse depression.

From baseline to cycle 9, up to 66 days.
P13K Status by Response
大体时间:Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.

Phosphoinositide 3-kinase (PI3K) biomarker status, either positive or negative, analyzed using established methods from tumor biopsies. P13K status is reported by response, either responder (CR or PR) or non-responder (SD or PR).

Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Robert Haddad, MD、Brigham and Women's Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年9月29日

初级完成 (实际的)

2019年12月6日

研究完成 (实际的)

2022年1月1日

研究注册日期

首次提交

2014年4月1日

首先提交符合 QC 标准的

2014年4月11日

首次发布 (估计的)

2014年4月15日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年10月21日

最后验证

2024年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅